Although costs and side effects prevented approval of this agent for this particular indication, the trial demonstrated a causal role of the interleukin-1 beta pathway for the development of cardiovascular complications in patients with previous myocardial infarction and raised circulating C-reactive protein [29]. The gene discussed is IL1B; the disease is myocardial infarction.